Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc.

Date Founded



181 Oyster Point Boulevard,South San Francisco, CA 94080

Type of Company


Employees (Worldwide)



Medical Support Services
Holding Companies

Company Description

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Global Blood Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial & Accounting Officer

Chief Commercial Officer

Chief Scientific Officer

Chief Legal Officer

Chief Business & Strategy Officer

Chief Human Resources Officer

Executive Vice President & Head of Research & Development

Senior Vice President, Head of Medical Affairs & Program Team Leader, Voxelotor

Head of Intellectual Property

Board of Directors

Former Chief Financial Officer at Gilead Sciences, Inc.

Former Governor of Massachusetts

Founding Director at Stanford Distinguished Careers Institute

President & Chief Executive Officer at Global Blood Therapeutics, Inc.

Former President-Europe & Canada Region at Merck & Co., Inc.

Chairman & Chief Executive Officer at San Francisco State University - The Willie L. Brown, Jr. Institute of Politics & Public Service

Chief Medical Officer & Senior Vice President at Bioverativ Therapeutics, Inc.

Former Senior Vice President, Human Resources at Merck & Co., Inc.

Partner at Corvus Pharmaceuticals, Inc.

Paths to Global Blood Therapeutics, Inc.
Potential Connections via
Relationship Science
Global Blood Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Details Hidden

BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients.

Details Hidden

Casdin Capital seeks to realize superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. Their portfolio is generally comprised of small to mid-sized issuers in the following life sciences and healthcare sub-sectors: life sciences instrumentation and information technology, medical testing, drug development and distribution, synthetic biology and agriculture, livestock management and energy production. In addition, the firm also has discretion to invest in certain foreign equity securities if they determine that investments in such securities could generate risk-adjusted returns for their clients. Casdin Capital employs a primary research-intensive approach to investing that is thematically driven and fundamentally based and uses a range of investment strategies, primarily investing in publicly-traded equity or equivalent securities, both long and short, as well as a broad array of other securities.

Recent Transactions
Details Hidden

Global Blood Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Global Blood Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Global Blood Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock


Advised onGlobal Blood Therapeutics, Inc. issued . USD Common Stock

Escrow Agent

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Head of Investment Banking

Advised onGlobal Blood Therapeutics, Inc. issued . USD Common Stock


Advised onGlobal Blood Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Senior Counsel at Davis Polk & Wardwell LLP

Senior Advisor

Inventor of the Anti-Epileptic Drug Vigabatrin at Merrell Dow Pharmaceuticals, Inc.


Executive Vice President & Head of Research & Development at Global Blood Therapeutics, Inc.

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Net Profit
Total Equity
TEVNet Income
Total Debt
Enterprise Value / Sales
Debt TEV
Non-Profit Donations & Grants
Details Hidden

Deerfield Management Co. LP invests in companies located in the US. The firm target companies operating in broad range of industries. They provides financing for buyout transactions to private and public.

Details Hidden

Partner & Chief Technology Officer at Third Rock Ventures LLC

Details Hidden

Perceptive Advisors (Private Equity) invests in healthcare companies located globally. The firm target companies operating in the fields of biopharma, medical devices, diagnostics, life science research and healthcare information technology. They provides financing in the form of crossover rounds, leading IPOs, early and later stage capital requirements and public follow on financings. It invests in both public and private companies.

University of California Investment Services & Portfolio Management | Oakland, CA

The University is governed by The Regents, which under Article IX, Section 9 of the California Constitution has "full powers of organization and governance" subject only to very specific areas of legislative control. The article states that "the university shall be entirely independent of all political and sectarian influence and kept free therefrom in the appointment of its Regents and in the administration of its affairs." Board Membership Article IX, Section 9 was drafted in 1878 after a decade of political conflict demonstrated the importance of sheltering the university from shifting political winds. The board consists of 26 members: 18 regents are appointed by the governor for 12-year terms One is a student appointed by the Regents to a one-year term Seven are ex officio members -- the Governor, Lieutenant Governor, Speaker of the Assembly, Superintendent of Public Instruction, president and vice president of the Alumni Associations of UC and the UC president. In addition, two faculty members -- the chair and vice chair of the Academic Council -- sit on the board as non-voting members. Board Officers The Governor is officially the president of the Board of Regents; however, in practice the presiding officer of the Regents is the Chairman of the Board, elected from among its body for a one-year term, beginning July 1. The current Chairman is Regent Sherry Lansing. The Vice Chairman is Regent Bruce Varner. The Regents appoints Officers of The Regents: the General Counsel; the Chief Investment Officer; the Secretary and Chief of Staff; and the Chief Compliance and Audit Officer. Former Regents Here is a list of individuals who have served as Regents of the University of California: Former Regents Committees and Meetings The Regents operates through 10 standing committees: Compliance and Audit, Compensation, Educational Policy, Finance, Governance, Grounds and Buildings, Health Services, Investments, Long Range Planning, and Oversight of the Department of Energy Laboratories. The Regents meets six times a year every other month in two-day meetings

Roche Holding AG Medical Support Services | Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Syros Pharmaceuticals, Inc. Biotechnology | Cambridge, MA

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425 and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

bluebird bio, Inc. Biotechnology - Cambridge, MA

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Global Blood Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Global Blood Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Global Blood Therapeutics, Inc..